February 4, 2019 by Chain Drug Review
CVS Pharmacy, Judy Sansone
February 4, 2019, News
WOONSOCKET, R.I. — CVS Pharmacy has expanded the responsibilities of Judy Sansone, the chain’s senior vice president of front-store business and chief merchant. In addition, George Coleman has been promoted to senior vice president of merchandising, reporting to Sansone. He had been vice president of merchandising for consumer health care. Sansone’s team will be responsible
February 4, 2019 by Chain Drug Review
Microsoft, WBA
February 4, 2019, News
DEERFIELD, Ill. — Walgreens Boots Alliance (WBA) and Microsoft Corp. have teamed up to develop new health care delivery models, technology and retail innovations to advance and improve the future of health care. The companies will combine the power of Microsoft Azure, Microsoft’s cloud and artificial intelligence platform, health care investments, and new retail solutions
February 4, 2019 by Chain Drug Review
CVS, CVS Beauty Mark
February 4, 2019, News
WOONSOCKET, R.I. — CVS Pharmacy, the retail division of CVS Health, announced significant progress toward the goal of full transparency for all of its beauty imagery by the end of 2020 and its efforts to create new industry standards for post-production alterations of beauty imagery. Just one year after the company made the commitment to
February 4, 2019 by Chain Drug Review
DIR fee reform, NACDS
February 4, 2019, News
ARLINGTON, Va. — The National Association of Chain Drug Stores has submitted extensive and thoroughly documented comments to the Centers for Medicare and Medicaid Services (CMS) in support of the agency’s proposal to reform direct and indirect remuneration (DIR) fees — reform that relates directly to reducing patients’ out-of-pocket drug costs. NACDS issued its comments
February 4, 2019 by Chain Drug Review
Health Mart, Nimesh Jhaveri
February 4, 2019, News
IRVING, Texas — Nimesh Jhaveri has joined the Health Mart family of community pharmacies as president. Jhaveri, who has 30 years of hands-on pharmacy experience, started in his new role on October 31. As president, Jhaveri is responsible for developing strategies supporting the goals and success of more than 5,000 Health Mart pharmacies. In his
February 4, 2019 by Chain Drug Review
brick-and-mortar retailers, digital shopping
February 4, 2019, Opinion
Despite the growing influence of online and digital shopping, over 70% of consumers prefer to shop for consumer packaged goods from retailers with a physical presence — whether shopping in-store or online — as opposed to 29% who shop primarily online, according to results from a recent survey by DXC Technology published in an IDC
February 4, 2019 by Jeffrey Woldt
Stefano Pessina, Walgreens Boots Alliance (WBA)
February 4, 2019, Opinion
Walgreens Boots Alliance has entered the early stages of a profound transition, one that will see the organization pivot from a store-first to a digital-first model. Any lingering doubts about the direction the company is headed were put to rest earlier this month when WBA unveiled a seven-year agreement with Microsoft to harness the power
January 24, 2019 by Justin Bates
Justin Bates, Neighbourhood Pharmacy Association of Canada
Featured Articles, January 7, 2019, Leading Headlines, Pharmacy
Editor’s note: This was part of CDR’s 2019 Pharmacy Outlook in the January 7 issue. Looking ahead to 2019, the pharmacy business is poised to be more disrupted than ever before. Over the past 10 years, our members have successfully navigated a number of headwinds to their operating and regulatory environments, including price compression, regulatory
January 23, 2019 by Jim Greenwood
biotech industry, Biotechnology Innovation Organization, Jim Greenwood
Featured Articles, January 7, 2019, Leading Headlines, Pharmacy
Editor’s note: This was part of CDR’s 2019 Pharmacy Outlook in the January 7 issue. For much of 2018, capital markets for biotech investment were strong. Some 53 biotech companies went public with more than $5.4 billion in funding, putting the biotech industry on track for the second-best year for IPOs in a decade. And
January 22, 2019 by Chip Davis
Association for Accessible Medicines, Chip Davis
Featured Articles, January 7, 2019, Leading Headlines, Pharmacy
Editor’s note: This was part of CDR’s 2019 Pharmacy Outlook in the January 7 issue. This past June, Secretary of Health and Human Services Alex Azar told the Senate Finance Committee, “We need a strong, robust generic market.” He followed this statement with an observation that resonated for many of the member companies of the
January 22, 2019 by Randy Burt and Todd Huseby
A.T. Kearney, cannabidiol (CBD), legal cannabis-based products, Randy Burt, Todd Huseby
Business, January 21, 2019, Leading Headlines, Opinion, Retail News
Editor’s note: This is Part I of an article that ran in the 1/21/19 issue of CDR. As legal cannabis-based products continue to find their way to market, promising to redefine entire categories from health, beauty and wellness to food and beverage in their wake, most chain drug retailers are scrambling to calculate the impact
January 21, 2019 by Chain Drug Review
Affordable Care Act
January 21, 2019, News
WASHINGTON — Since becoming law in March 2010, the Patient Protection and Affordable Care Act, known more commonly as the ACA or Obamacare, has been a burr under the saddle of Republicans — and President Trump in particular. While some Americans embraced the ACA as a vehicle for them to get insurance and for its
January 21, 2019 by Chain Drug Review
Alex Gourlay, WBA
January 21, 2019, News
SAN FRANCISCO — During a fireside chat at the annual J.P. Morgan Healthcare Conference here earlier this month, Walgreens Boots Alliance (WBA) co-chief operating officer Alex Gourlay spoke to the number of partnerships the company has brought to the marketplace as well as the future of health care. WBA has always viewed vertical integration positively,
January 21, 2019 by Chain Drug Review
John Standley, Rite Aid
January 21, 2019, News
CAMP HILL, Pa. — Rite Aid Corp.’s flagging stock price notwithstanding, the chain has “great opportunities for growth,” chief executive officer John Standley said this month at the annual JP Morgan Healthcare Conference. Standley spoke less than a week after the New York Stock Exchange notified the retailer that it was no longer in compliance